-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Objective: One of the histological features of systemic sclerosis (SSc) is an increase in the number of dermal myofibroblasts, and transforming growth factor beta (TGF β ) plays a role in promoting the differentiation of fibroblasts into myofibroblasts and leading to dermal fibros.
Objective: One of the histological features of systemic sclerosis (SSc) is an increase in the number of dermal myofibroblasts, and transforming growth factor beta (TGF β ) plays a role in promoting the differentiation of fibroblasts into myofibroblasts and leading to dermal fibros.
Methods: Fibroblasts obtained from the skin of SSc patients were culturedin the presence or absence of TGF.
Results: Addition of CDK4/6 inhibitors to cell cultures inhibited the proliferation of human dermal SSc fibroblasts and their TGFβ -induced myofibroblast differentiation, but not both canonical and non-canonical TGFβ signalin.
Conclusions: The results of this study demonstrate the therapeutic efficacy of CDK4/6 inhibitors in skin fibrosis when used as monotherapy or in combination with TGFβR inhibitor.
Source: Yamamoto,.
Yamamoto,.
, Saito,.
, Hosoya,.
, Kawahata,.
, Asano,.
, Sato,.
, Mizoguchi,.
, Yasuda,.
and Kohsaka,.
(2022), Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Dermal Fibrosis in Murine Models of Systemic Scleros.
Arthritis Rheumatol, 74: 860-87https://d.
org/11002/a.
42042Leave a comment here
